Professor and Chairman of Urology, Emory University School of Medicine
Urology
Dr. Martin G. Sanda, MD
|
|
Give Review
Martin Sanda is an expert in the field of Urology. He researched medicine at Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is one of the top medical schools in the US. Columbia University College of Physicians & Surgeons is ranked 8/52 in Research/PrimaryCare. He over the years received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "Boston Magazine". Martin Sanda is also a published doctor. He has 95 paper published. The most recent paper is: Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. Doctor Martin G. Sanda, MD accepts Medicare.
Publications
- Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
- RNA biomarkers to facilitate the identification of aggressive prostate Cancer.
- Minimally important difference for the expanded prostate Cancer index composite short form.
- Quality of Life After Primary Treatment for Localized Prostate Cancer: Long-term Considerations.
- The Prostate Health Index (phi) Selectively Identifies Clinically-Significant Prostate Cancer.
- Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
- Prostate Cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.
- Recommended patient-reported core set of symptoms to measure in prostate Cancer treatment trials.
- Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation.
- Prostate Cancer Prevention Trial Risk Calculator 2.0 for the Prediction of Low- vs High-grade Prostate Cancer.
- Measuring and Predicting Prostate Cancer Related Quality of Life Changes Using EPIC for Clinical Practice.
- Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate Cancer.
- Benchmarks for Operative Outcomes of Robotic and Open Radical Prostatectomy: Results from the Health Professionals Follow-up Study.
- Satisfaction with Information Used to Choose Prostate Cancer Treatment.
- Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate Cancer.
- Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate Cancer.
- Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and Sexual quality of life: results of a multicenter prospective study.
- Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.
- Diagnosis of relevant prostate Cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies.
- Multi-institutional Prospective Evaluation of Bowel Quality of Life After Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated ...
- Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
- Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate Cancer.
- Uncertainty and perception of danger among patients undergoing treatment for prostate Cancer.
- Partners' Long-term Appraisal of Their Caregiving Experience, Marital Satisfaction, Sexual Satisfaction, and Quality of Life 2 Years After Prostate Cancer Treatment.
- Updating risk prediction tools: A case study in prostate Cancer.
- Watchful waiting and quality of life among prostate Cancer survivors in the physicians' health study.
- Selective detection of histologically aggressive prostate Cancer: An Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with val...
- Prediction of erectile function following treatment for prostate Cancer.
- Expanded prostate Cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the rout...
- Urine TMPRSS2:ERG fusion transcript stratifies prostate Cancer risk in men with elevated serum PSA.
- Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate Cancer.
- A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in th...
- Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate Cancer.
- The Role of the Transcription Factor SIM2 in Prostate Cancer.
- Development and validation of an abbreviated version of the expanded prostate Cancer index composite instrument for measuring health-related quality of life among pros...
- Editorial comment. Acute lower urinary tract symptoms after Prostate brachytherapy with cesium-131.
- Urinary obstructive problems exposed but hormonal health-related quality-of-life concerns eschewed in prostate Cancer quality-of-life study.
- Comparison of validated instruments measuring Sexual function in men.
- Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-Antigen in transgenic mice.
- Reduction in patient-reported acute morbidity in prostate Cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume marg...
- A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate Cancer detection and correlating with ca...
- Defective NKT cell activation by CD1d+ TRAMP Prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide.
- Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate Cancer detection.
- Detection of TMPRSS2-ERG fusion gene expression in prostate Cancer specimens by a novel assay using branched DNA.
- A Branched DNA Assay for Detecting TMPRSS2-ERG Fusions.
- Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate Cancer in a nationwide cohort.
- Further perspectives on treating localized prostate Cancer.
- Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate Cancer.
- Prevalence of TMPRSS2-ERG fusion prostate Cancer among men undergoing prostate biopsy in the United States.
- Editorial comment. Nerve sparing during radical Prostatectomy is associated with better recovery of urinary continence.
- A 64-year-old man with low-risk prostate Cancer: review of prostate Cancer treatment.
- Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4.
- Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the Bladder.
- Patterns of care for radical Prostatectomy in the United States from 2003 to 2005.
- Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential mUrine targets for preclinical developme...
- Longitudinal analysis of a model to predict quality of life in prostate Cancer patients and their spouses.
- [-2]proenzyme prostate specific antigen for prostate Cancer detection: a national Cancer institute early detection research network validation study.
- Partially circumventing peripheral tolerance for oncogene-specific prostate Cancer immunotherapy.
- Is androgen suppression therapy associated with early onset of fatal myocardial infarction?
- Quality of life and satisfaction with outcome among prostate-Cancer survivors.
- Measuring health-related quality of life consequences from primary treatment for early-stage prostate Cancer.
- Lower limits of detection using magnetic resonance imaging for solid components in cystic Renal neoplasms.
- Living with prostate Cancer: patients' and spouses' psychosocial status and quality of life.
- Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate Cancer surgery or radiotherapy.
- Obesity adversely affects health related quality of life before and after radical retropubic Prostatectomy.
- Use of medications or devices for erectile dysfunction among long-term prostate Cancer treatment survivors: potential influence of sexual motivation and/or indifference.
- Prognostic factors in lymph node-positive prostate Cancer.
- Autoantibody signatures in prostate Cancer.
- Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate Cancer.
- Long-term outcomes among localized prostate Cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.
- Patient, surgeon, and treatment characteristics associated with homologous Blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram...
- Humoral immune response to alpha-methylacyl-CoA racemase and prostate Cancer.
- Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate Cancer.
- Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate Cancer.
- Racial/ethnic disparities in the treatment of localized/regional prostate Cancer.
- Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate Cancer.
- The role of metastasis-associated protein 1 in prostate Cancer progression.
- Postprostatectomy Cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline Cancer severity.
- The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate Cancer.
- Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical Prostatectomy.
- Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate Cancer.
- Contemporary preoperative parameters predict Cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
- Determinants of long-term sexual health outcome after radical Prostatectomy measured by a validated instrument.
- Use of quality indicators to evaluate the care of patients with localized Prostate carcinoma.
- Antigen-specific tumor vaccine efficacy in vivo against prostate Cancer with low class I MHC requires competent class II MHC.
- Contemporary diagnosis and management of Renal angiomyolipoma.
- Prostate cancer involving the Bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer.
- Huntingtin-interacting protein 1 is overexpressed in prostate and colon Cancer and is critical for cellular survival.
- Preoperative parameters for predicting early prostate Cancer recurrence after radical prostatectomy.
- alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate Cancer.
- Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after Prostate brachytherapy.
- Daily Prostate targeting using implanted radiopaque markers.
- Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate Cancer.
- Immunization with a Peptide Containing MHC Class I and II Epitopes Derived from the Tumor Antigen SIM2 Induces an Effective CD4 and CD8 T-Cell Response.
Schools
Columbia University College Of Physicians and Surgeons
Johns Hopkins Hospital Urology
National Cancer Institute
Yale University
Procedures Preformed
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- Orchiectomy
- Pelvic Exenteration (For: Gynecologic, Urinary, or Colorectal Malignancy)
- Prostate Removal
- View All
Conditions Treated
- Bladder Cancer
- Blood in Urine (Hematuria)
- Chronic Kidney Diseases
- Diverticulum of Bladder
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Boston Magazine
Education
-
Johns Hopkins University -
Virginia Commonwealth University Health System -
Columbia University College of Physicians & Surgeons
Hospital
-
Emory University Hospital -
Emory Saint Joseph's Hospital of Atlanta -
Grady Memorial Hospital -
Beth Israel Deaconess Medical Center
Drug Facts
| NPI NUMBER | 1710093679 | |
| NPPES Provider LastName | SANDA | |
| NPPES Provider FirstName | MARTIN | |
| NPPES Provider ZIPCode | 303220001 | |
| NPPES Provider State | GA | |
| Specialty Description | Urology | |
| Total Claim Count | 55.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710093679 |
| Last Name Of The Provider | SANDA |
| First Name Of The Provider | MARTIN |
| View All |
Similar Doctors
|
|
Dr. William Nabors, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Raymond W. Pak, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Nikhil L. Shah, DO |
|
|
Dr. Joan Hader, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ned M. Franco, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. William M. Scaljon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edwin A. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wayland Hsiao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hadley Wyre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samuel A. David, MD |